Allecra Therapeutics, a three-year old biotech company co-located in Germany and France, has raised €22 million in a Series B investment round to finance the development of an antibiotic combination therapy designed to treat Gram-negative bacteria. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
